MDM2 SNP309T>G Polymorphism with Hepatocellular Carcinoma Risk: A Meta-analysis

Archives of Medical Research

Volumn 42, Issue 2, 2011, Pages 149-155

  Liu, Guo Yuan ^a   Jiang, De Ke ^a   Shen, Su Qin ^a   Yu, Long ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; MDM2 SNP309T>G; Meta analysis; Polymorphism

Indexed keywords

PROTEIN MDM2;

ADULT; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENETIC MODEL; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDLINE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, GENETIC; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 79955723279     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.02.002     Document Type: Article

References (38)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. Yuen M.F., Hou J.L., Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009, 24:346-353.
3. Soini Y., Chia S.C., Bennett W.P., et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 1996, 17:1007-1012.
4. Donato F., Tagger A., Gelatti U., et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155:323-333.
5. Hellerbrand C., Pöppl A., Hartmann A., et al. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol 2003, 1:279-284.
6. Aravalli R.N., Steer C.J., Cressman E.N. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008, 48:2047-2063.
7. El-Kafrawy S.A., Abdel-Hamid M., El-Daly M., et al. P53 mutations in hepatocellular carcinoma patients in Egypt. Int J Hyg Environ Health 2005, 208:263-270.
8. Weihrauch M., Lehnert G., Kockerling F., et al. p53 mutation pattern in hepatocellular carcinoma in workers exposed to vinyl chloride. Cancer 2000, 88:1030-1036.
9. Michael D., Oren M. The p53-MDM2 module and the ubiquitin system. Semin Cancer Biol 2003, 13:49-58.
10. Endo K., Ueda T., Ohta T., et al. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 2000, 20:209-215.
11. Schoniger-Hekele M., Hanel S., Wrba F., et al. Hepatocellular carcinoma-survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int 2005, 25:62-69.
12. Bond G.L., Hu W., Bond E.E., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
13. Wilkening S., Bermejo J.L., Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007, 28:2262-2267.
14. Hu Z., Jin G., Wang L., et al. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 2007, 16:2717-2723.
15. Ohmiya N., Taguchi A., Mabuchi N., et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006, 24:4434-4440.
16. Ma H., Hu Z., Zhai X., et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 2006, 240:261-267.
17. Li G., Zhai X., Zhang Z., et al. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006, 27:2028-2033.
18. Onat O.E., Tez M., Ozcelik T., et al. MDM2 T309 G polymorphism is associated with bladder cancer. Anticancer Res 2006, 26:3473-3475.
19. Fang F., Yu X.J., Yu L., et al. MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med Oncol 2010 May 26, (Epub ahead of print).
20. Dharel N., Kato N., Muroyama R., et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006, 12:4867-4871.
21. Yoon Y.J., Chang H.Y., Ahn S.H., et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008, 29:1192-1196.
22. Leu J.D., Lin I.F., Sun Y.F., et al. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol 2009, 15:5592-5597.
23. Ezzikouri S., El Feydi A.E., Afifi R., et al. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev 2009, 32:380-385.
24. Akkiz H., Sümbül A.T., Bayram S., et al. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol 2010, 34:448-452.
25. Cochran W.G. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
26. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
27. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
28. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 1999, 8:15-17.
29. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
30. Dual S., Tweedie R. A nonparametric ''trim and fill'' method of accounting for publication bias in meta-analysis. J Am Stat Assoc 2000, 95:89-98.
31. Acun T., Terzioĝlu-Kara E., Konu O., et al. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma. Mutat Res 2010, 684:106-108.
32. Dongiovanni P., Fracanzani A.L., Cairo G., et al. Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol 2010, 176:1006-1017.
33. Economopoulos K.P., Sergentanis T.N. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat 2010, 120:211-216.
34. Gui X.H., Qiu L.X., Zhang H.F., et al. MDM2 309 T/G polymorphism is associated with lung cancer risk among Asians. Eur J Cancer 2009, 45:2023-2026.
35. Qiu S.J., Ye S.L., Wu Z.Q., et al. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J Cancer Res Clin Oncol 1998, 124:253-258.
36. Jablkowski M., Bocian A., Bialkowska J., et al. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma. J Exp Clin Cancer Res 2005, 24:117-125.
37. Hong Y., Miao X., Zhang X., et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005, 65:9582-9587.
38. Hirata H., Hinoda Y., Kikuno N., et al. MDM2SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 2007, 13:4123-4129.